Biology Reference
In-Depth Information
Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP (2002) Immunogenicity of a recom-
binant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J
21:133-138
Morello CS, Ye M, Spector DH (2002) Development of a vaccine against murine cytomegalovirus
(MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-
term, complete protection against viral replication. J Virol 76:4822-4835
Morello CS, Ye M, Hung S, Kelley LA, Spector DH (2005) Systemic priming-boosting immuniza-
tion with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine
provides long-term protection against viral replication following systemic or mucosal MCMV
challenge. J Virol 79:159-175
Morello CS, Kelley LA, Munks MW, Hill AB, Spector DH (2007) DNA immunization using highly
conserved murine cytomegalovirus genes encoding homologs of human cytomegalovirus
UL54 (DNA polymerase) and UL105 (helicase) elicits strong CD8 T-cell responses and is
protective against systemic challenge. J Virol 81:7766-7775
Murph JR, Baron JC, Brown CK, Ebelhack CL, Bale JF Jr (1991) The occupational risk of
cytomegalovirus infection among day-care providers. JAMA 265:603-608
Nigro G, Adler SP, La Torre R, Best AM; Congenital Cytomegalovirus Collaborating Group
(2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl
J Med 353:1350-1362
Pass RF (1996) Immunization strategy for prevention of congenital cytomegalovirus infection.
Infect Agents Dis 5:240-244
Pass RF, Hutto C, Lyon MD, Cloud G (1990) Increased rate of cytomegalovirus infection among
day care center workers. Pediatr Infect Dis J 9:465-467
Pass RF, Duliege AM, Boppana S, Sekulovich R, Percell S, Britt W, Burke RL (1999) A subunit
cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.
J Infect Dis 180:970-975
Pepperl S, Munster J, Mach M, Harris JR, Plachter B (2000) Dense bodies of human cytomegalo-
virus induce both humoral and cellular immune responses in the absence of viral gene expres-
sion. J Virol 74:6132-6146
Plotkin SA, Higgins R, Kurtz JB, Morris PJ, Campbell DA Jr, Shope TC, Spector SA, Dankner
WM (1994) Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal
transplant recipients. Transplantation 58:1176-1178
Rapp M, Messerle M, Lucin P, Koszinowski UH (1993) In vivo protection studies with mCMV
glycoproteins gB and gH expressed by vaccinia virus. In: Michelson S, Plotkin SA (eds)
Multidisciplinary approach to understanding cytomegalovirus disease. Elsevier, Amsterdam,
pp 327-332
Reap EA, Dryga SA, Morris J, Rivers B, Norberg PK, Olmsted RA, Chulay JD (2007) Cellular
and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus
pp65, IE1, and gB proteins. Clin Vaccine Immunol 14:748-755
Revello MG, Gerna G (2002) Diagnosis and management of human cytomegalovirus infection in
the mother, fetus, and newborn infant. Clin Microbiol Rev 15:680-715
Schleiss MR, Heineman TC (2005) Progress toward an elusive goal: current status of cytomega-
lovirus vaccines. Expert Rev Vaccines 4:381-406
Schleiss MR, Bourne N, Stroup G, Bravo FJ, Jensen NJ, Bernstein DI (2004) Protection against
congenital cytomegalovirus (CMV) infection and disease in guinea pigs conferred by a puri-
fied recombinant glycoprotein B (gB) vaccine. J Infect Dis 189:1374-1381
Schleiss MR, Stroup G, Pogorzelski K, McGregor A (2006) Protection against congenital cytome-
galovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome
(BAC)-based DNA vaccine. Vaccine 24:6175-6186
Schleiss MR, Lacayo JC, Belkaid Y, McGregor A, Stroup G, Rayner J, Alterson K, Chulay JD,
Smith JF (2007) Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog)
vaccine induces humoral and cellular immunity and improves pregnancy outcome in the
guinea pig model of congenital cytomegalovirus infection. J Infect Dis 195:789-798
